Sepsis can turn the immune system’s emergency response into a source of widespread tissue damage. When infection triggers an uncontrolled inflammatory cascade, the lungs are among the first organs to suffer. Blood vessels become leaky, immune cells accumulate in lung tissue, and the air sacs responsible for oxygen exchange can fill with fluid. This condition, known as sepsis-induced acute lung injury, can progress to acute respiratory distress syndrome and remains a major cause of death in intensive-care units. A study by Zhang, Guo, He and colleagues now reports that extracellular vesicles released by human adipose-derived mesenchymal stem cells may protect the lungs by changing how macrophages process fats and by encouraging them to produce the anti-inflammatory molecule interleukin-10.
The findings, published in Cell Death Discovery, focus on a biological communication system that is attracting intense interest in regenerative medicine. Extracellular vesicles are nanoscale membrane-bound particles released by cells. They carry combinations of proteins, lipids, messenger RNAs and regulatory microRNAs, allowing one cell to influence the behavior of another without direct contact. Unlike whole-cell therapies, vesicles do not replicate and are less likely to become trapped in tissues as living cells can be. Their molecular cargo can nevertheless alter gene activity, cellular metabolism and immune behavior. In this case, vesicles derived from human adipose-derived mesenchymal stem cells appear to deliver signals that redirect macrophages away from a damaging inflammatory state.
Macrophages are essential immune sentinels in the lungs. They recognize danger signals, engulf microbes and debris, and release chemical messengers that coordinate the response to injury. During sepsis, however, macrophages can become excessively activated. Their secretion of inflammatory cytokines and their accumulation of oxidized or otherwise dysfunctional lipids can amplify vascular leakage and tissue destruction. Lipid metabolism is not simply a matter of energy storage in these cells. Fatty acids and cholesterol-derived molecules also act as signaling compounds, influence mitochondrial performance and shape the expression of immune genes. By reprogramming this metabolic network, the vesicles may address a fundamental driver of lung inflammation rather than suppressing a single downstream cytokine.
The study identifies an ABCF1/CPT1A/IL-10 axis as the central pathway behind the protective effect. ABCF1, or ATP-binding cassette subfamily F member 1, is a regulatory protein associated with inflammatory control and cellular responses to metabolic stress. CPT1A, carnitine palmitoyltransferase 1A, controls a critical step in the transport of long-chain fatty acids into mitochondria. Once inside mitochondria, these fatty acids can undergo beta-oxidation, a process that generates energy and produces metabolic intermediates capable of influencing immune function. The researchers’ model proposes that vesicle treatment increases or activates ABCF1, which in turn supports CPT1A-dependent fatty-acid utilization. This metabolic shift is linked to greater production of IL-10, a cytokine known for restraining excessive inflammation.
The importance of the pathway lies in the relationship between metabolism and immune identity. Macrophages are often described as existing along a spectrum between inflammatory and repair-oriented states, although their biology is considerably more complex than a simple two-category model. In sepsis, altered mitochondrial activity and lipid handling can lock these cells into a destructive cycle. Poorly processed lipids may accumulate, oxidative stress may rise, and inflammatory signaling can become self-reinforcing. Enhanced fatty-acid oxidation through CPT1A could help restore mitochondrial balance, while ABCF1 may function as an upstream regulator connecting metabolic remodeling to immune gene expression. Increased IL-10 would then provide a braking mechanism, limiting the production of inflammatory mediators and reducing collateral injury in the lung.
The reported results suggest that the vesicles do more than deliver a generic anti-inflammatory signal. They appear to act as precision packages that influence a defined molecular sequence inside macrophages. In the proposed mechanism, vesicle cargo reaches recipient immune cells and modifies the activity of ABCF1. This change promotes CPT1A-associated lipid oxidation and alters the intracellular metabolic environment. The resulting state favors IL-10 expression, helping macrophages adopt a response that is less damaging to surrounding tissue. Such a mechanism is particularly significant in sepsis, where broad immune suppression can be dangerous. A therapy that reduces harmful inflammation while preserving the macrophage’s ability to respond to pathogens would be more desirable than indiscriminately shutting down immunity.
The work also highlights why adipose tissue is being explored as a source of therapeutic vesicles. Human adipose-derived mesenchymal stem cells can be obtained from an accessible tissue reservoir and expanded under laboratory conditions. These cells secrete vesicles containing bioactive molecules that may influence immunity, tissue repair and vascular function. The therapeutic effect does not depend on the stem cells permanently engrafting in the damaged lung; instead, it may be mediated by the messages carried in their vesicles. This distinction could simplify treatment development, although manufacturing remains a demanding challenge. Researchers must control the cells’ culture conditions, isolate vesicles consistently, characterize their contents and ensure that preparations are free of contaminants such as endotoxin, protein aggregates or unwanted nucleic acids.
Acute lung injury is a compelling target for this approach because the disease involves several interconnected processes. Inflammatory macrophages interact with endothelial cells lining the blood vessels, epithelial cells lining the airways and neutrophils recruited from the circulation. Damage to the endothelial barrier allows plasma to enter the air spaces, while injury to epithelial cells disrupts fluid clearance and weakens the lung’s defense system. Metabolic reprogramming of macrophages could influence this entire network by reducing the signals that recruit and activate additional immune cells. If the ABCF1/CPT1A/IL-10 pathway functions as described, the treatment could potentially limit inflammation while supporting restoration of the pulmonary barrier. The study therefore places macrophage metabolism at the center of a disease traditionally viewed mainly through the lens of cytokine excess.
Even so, the findings represent a step toward translation rather than an immediately available treatment for patients with sepsis. Vesicle therapies must be tested across multiple experimental systems and eventually in carefully designed clinical trials. Important questions remain about dose, timing and delivery. Sepsis is biologically diverse: the cause of infection, the patient’s age, the stage of immune activation and the presence of organ failure can all alter treatment responses. It will also be necessary to determine whether vesicles reach lung macrophages efficiently after intravenous administration, how long their effects last and whether repeated dosing is safe. Because IL-10 can suppress antimicrobial activity under some circumstances, researchers will need to establish whether increasing it through this pathway protects tissue without impairing pathogen clearance.
The study nevertheless offers a striking example of how cell-free therapies may reshape the immune system by targeting metabolism. Rather than treating sepsis-induced lung injury as a problem caused by one inflammatory molecule, the research connects vesicle communication with fatty-acid oxidation, macrophage behavior and cytokine regulation. The ABCF1/CPT1A/IL-10 axis provides a mechanistic framework that could guide the design of more selective therapies and serve as a set of biomarkers for identifying responding patients. If future work confirms the findings in rigorous animal studies and human trials, extracellular vesicles from adipose-derived mesenchymal stem cells could become a platform for restoring immune balance in one of critical care’s most difficult conditions. For now, the work strengthens the case that controlling what immune cells do with lipids may be as important as controlling the inflammatory signals they release.
Subject of Research: Extracellular vesicles from human adipose-derived mesenchymal stem cells and their effects on macrophage lipid metabolism in sepsis-induced acute lung injury.
Article Title: Extracellular vesicles from human adipose-derived mesenchymal stem cells reprogram macrophage lipid metabolism via the ABCF1/CPT1A/IL-10 axis to mitigate sepsis-induced acute lung injury.
Article References:
Zhang, L., Guo, D., He, Q. et al. Extracellular vesicles from human adipose-derived mesenchymal stem cells reprogram macrophage lipid metabolism via the ABCF1/CPT1A/IL-10 axis to mitigate sepsis-induced acute lung injury. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03192-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03192-x
Keywords: Sepsis; acute lung injury; extracellular vesicles; adipose-derived mesenchymal stem cells; macrophages; lipid metabolism; ABCF1; CPT1A; IL-10; immunometabolism.
